Literature DB >> 26807542

Synthesis and evaluation of dual antiplatelet activity of bispidine derivatives of N-substituted pyroglutamic acids.

Ankita Misra1, K S Anil Kumar2, Manish Jain1, Kirti Bajaj3, Shyamali Shandilya3, Smriti Srivastava1, Pankaj Shukla1, Manoj K Barthwal1, Madhu Dikshit1, Dinesh K Dikshit4.   

Abstract

N-aralkylpyroglutamides of substituted bispidine were prepared and evaluated for their ability to inhibit collagen induced platelet aggregation, both in vivo and in vitro. Some compounds showed high anti-platelet efficacy (in vitro) of which six inhibited both collagen as well as U46619 induced platelet aggregation with concentration dependent anti-platelet efficacy through dual mechanism. In particular, the compound 4j offered significant protection against collagen epinephrine induced pulmonary thromboembolism as well as ferric chloride induced arterial thrombosis, without affecting bleeding tendency in mice. Therefore, the present study suggests that the compound 4j displays a remarkable antithrombotic efficacy much better than aspirin and clopidogrel.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anti-platelet; Bispidine; Collagen; Pyroglutamic acid; U46619

Mesh:

Substances:

Year:  2016        PMID: 26807542     DOI: 10.1016/j.ejmech.2016.01.019

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  2 in total

1.  Aspirin & clopidogrel non-responsiveness & its association with genetic polymorphisms in patients with myocardial infarction.

Authors:  Chandra Prakash Pandey; Ankita Misra; Mahendra Pal Singh Negi; Babu Nageswararao Kanuri; Yashpal Singh Chhonker; Rabi Shanker Bhatta; Varun Shanker Narain; Madhu Dikshit
Journal:  Indian J Med Res       Date:  2019-07       Impact factor: 2.375

2.  Refinement of Mouse Protocols for the Study of Platelet Thromboembolic Responses In Vivo.

Authors:  Francesca Rauzi; Erica Smyth; Michael Emerson
Journal:  Thromb Haemost       Date:  2017-12-06       Impact factor: 5.249

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.